An Anti-Cancer Drug Candidate CYC116 Suppresses Type I Hypersensitive Immune Responses through the Inhibition of Fyn Kinase in Mast Cells

Mast cells are the most prominent effector cells of Type 1 hypersensitivity immune responses. CYC116 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl] pyrimidin-2-amine] is under development to be used as an anti-cancer drug, but the inhibitory effects of CYC116 on the activation o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomol Ther (Seoul)
Hlavní autoři: Park, Young Hwan, Kim, Hyun Woo, Kim, Hyuk Soon, Nam, Seung Taek, Lee, Dajeong, Lee, Min Bum, Min, Keun Young, Koo, Jimo, Kim, Su Jeong, Kim, Young Mi, Kim, Hyung Sik, Choi, Wahn Soo
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Society of Applied Pharmacology 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6513188/
https://ncbi.nlm.nih.gov/pubmed/30332888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4062/biomolther.2018.148
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky